These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19955336)

  • 21. Temsirolimus in the treatment of advanced renal cell carcinoma.
    Gore ME
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix87-8. PubMed ID: 17631601
    [No Abstract]   [Full Text] [Related]  

  • 22. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R; Boni JP; Ravaud A
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Everolimus.
    Houghton PJ
    Clin Cancer Res; 2010 Mar; 16(5):1368-72. PubMed ID: 20179227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
    Jebali M; Elaidi R; Brizard M; Fouque J; Takouchop C; Sabatier B; Oudard S; Medioni J
    BMC Cancer; 2017 Jan; 17(1):27. PubMed ID: 28061764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer.
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):512-3. PubMed ID: 26351813
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma.
    Kim KH; Yoon SH; Lee HJ; Kim HS; Shin SJ; Ahn JB; Rha SY
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):853-60. PubMed ID: 23978988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
    Blesius A; Beuselinck B; Chevreau C; Ravaud A; Rolland F; Oudard S; Escudier B
    Clin Genitourin Cancer; 2013 Jun; 11(2):128-33. PubMed ID: 23332872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sunitinib still fi rst-line therapy for metastatic renal cancer.
    Bagcchi S
    Lancet Oncol; 2014 Sep; 15(10):e420. PubMed ID: 25328943
    [No Abstract]   [Full Text] [Related]  

  • 29. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review.
    Agarwala SS; Case S
    Oncologist; 2010; 15(3):236-45. PubMed ID: 20215359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma.
    Mizuno R; Asano K; Mikami S; Nagata H; Kaneko G; Oya M
    Jpn J Clin Oncol; 2012 May; 42(5):442-6. PubMed ID: 22438405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lingual angioedema associated with everolimus.
    Mackenzie M; Wood LA
    Acta Oncol; 2010; 49(1):107-9. PubMed ID: 20100146
    [No Abstract]   [Full Text] [Related]  

  • 32. Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
    Huelsmann L; Kim DNW; Hannan R; Watumull LM; Brugarolas J
    Clin Genitourin Cancer; 2015 Aug; 13(4):e321-e323. PubMed ID: 25620636
    [No Abstract]   [Full Text] [Related]  

  • 33. Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 2012;61:826-33.
    Procopio G; Verzoni E; De Braud F
    Eur Urol; 2012 Jul; 62(1):e5-6; author reply e7-8. PubMed ID: 22487015
    [No Abstract]   [Full Text] [Related]  

  • 34. Changes in the diffusion capacity for carbon monoxide and the development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus.
    Park K; Kim HJ; Lee JL; Lee KH; Jeong IG; Song C; Hong BS; Hong J; Kim CS; Ahn H
    Anticancer Res; 2014 Oct; 34(10):5723-8. PubMed ID: 25275080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
    Oudard S; Medioni J; Aylllon J; Barrascourt E; Elaidi RT; Balcaceres J; Scotte F
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):705-17. PubMed ID: 19496707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.
    Di Lorenzo G; Casciano R; Malangone E; Buonerba C; Sherman S; Willet J; Wang X; Liu Z; De Placido S
    Expert Opin Pharmacother; 2011 Jul; 12(10):1491-7. PubMed ID: 21599551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Side-effects associated with targeted therapies in renal cell carcinoma.
    Soulières D
    Curr Opin Support Palliat Care; 2013 Sep; 7(3):254-7. PubMed ID: 23912383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
    Vogelzang NJ; Bhor M; Liu Z; Dhanda R; Hutson TE
    Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
    Bendtsen MAF; Grimm D; Bauer J; Wehland M; Wise P; Magnusson NE; Infanger M; Krüger M
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28796163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.